title: Outcome Study of Cobalt Based Stereotactic Body Radiation Therapy for Patients with Inoperable Stage III Non-small Cell Lung Cancer.
abstract: Aim of this paper is to retrospectively evaluate the efficacy and toxicity of specialized Body Cobalt based system (BCBS) treatment in the senior patients group (.65 years) with Stage III non-small cell lung carcinoma (NSCLC). A total of 49 patients (41 males and 8 females) with Stage III NSCLC according to UICC TNM classification (6(th) edition) were treated using OUR-QGD™ BCBS which was designed and manufactured in China. Post treatment evaluation with follow-up information was collected from April 2001 to December 2006 in our department. Median age of enrolled patients was 71 years old (65-85). Among those patients, 36 patients were pathologically identified with squamous cell carcinoma, and the other 13 patients were confirmed as adenocarcinoma. All patients were immobilized by vacuum based immobilization mold and then performed slow CT scan without any respiration gating devices. The daily radiation prescription dose was defined at 50% isodose line covering primary lesions and metastatic lymph nodes with doses from 2.5 to 6 Gy in 5 fractions per week according to the tumor stage and internally approved treatment protocols by the Institutional Review Board (IRB). Median daily dose and total delivery dose of 50% isodose line were 4 Gy and 41 Gy, respectively. In this study group, total of 3 patients received neoadjuvant cisplatin-based chemotherapy. Tumor response evaluated 12 weeks after radiation has demonstrated 13 complete responses (26.5%), 21 partial responses (42.9%). The overall survival (OS) rate of 1-year, 2-year and 3-year was 63.3%, 40.8% and 20.4%, respectively. The median and mean survival time was 22 and 24 months. All 49 patients tolerated the treatment well and have completed the planned therapy regiment. Body Cobalt based system treatment of those over 65 years old patients with Stage III NSCLC had reasonable and superior curative effect as well as local control, and at the same time without severe radiation side effects.
authors.affiliation: Radiation Oncology Department, PLA Air Force General Hospital, 30 Fucheng Rd., Beijing 100142 13146115858@163.com.
authors.forename: Yingjie
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Radiation Oncology Department, PLA Air Force General Hospital, 30 Fucheng Rd., Beijing 100142.
authors.forename: Fengming
authors.initials: F
authors.lastname: Lan
authors.affiliation: Radiation Oncology Department, PLA Air Force General Hospital, 30 Fucheng Rd., Beijing 100142.
authors.forename: Xiaoli
authors.initials: X
authors.lastname: Kang
authors.affiliation: Radiation Oncology Department, PLA Air Force General Hospital, 30 Fucheng Rd., Beijing 100142.
authors.forename: Yinjian
authors.initials: Y
authors.lastname: Shao
authors.affiliation: Radiation Oncology Department, PLA Air Force General Hospital, 30 Fucheng Rd., Beijing 100142.
authors.forename: Hongqi
authors.initials: H
authors.lastname: Li
authors.affiliation: Radiation Oncology Department, PLA Air Force General Hospital, 30 Fucheng Rd., Beijing 100142.
authors.forename: Ping
authors.initials: P
authors.lastname: Li
authors.affiliation: Radiation Oncology Department, PLA Air Force General Hospital, 30 Fucheng Rd., Beijing 100142.
authors.forename: Weizhang
authors.initials: W
authors.lastname: Wu
authors.affiliation: Radiation Oncology Department, PLA Air Force General Hospital, 30 Fucheng Rd., Beijing 100142.
authors.forename: Jidong
authors.initials: J
authors.lastname: Wang
authors.affiliation: Radiation Oncology Department, PLA Air Force General Hospital, 30 Fucheng Rd., Beijing 100142.
authors.forename: Dongshu
authors.initials: D
authors.lastname: Chang
authors.affiliation: Radiation Oncology Department, PLA Air Force General Hospital, 30 Fucheng Rd., Beijing 100142.
authors.forename: Yong
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Radiation Oncology Department, PLA Air Force General Hospital, 30 Fucheng Rd., Beijing 100142 13146115858@163.com.
authors.forename: Tingyi
authors.initials: T
authors.lastname: Xia
mesh_terms: D000230:Adenocarcinoma / Q000000981:diagnostic imaging / Q000473:pathology / Q000532:radiotherapy*; D000077192:Adenocarcinoma of Lung; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000000981:diagnostic imaging / Q000473:pathology / Q000532:radiotherapy*; D002294:Carcinoma, Squamous Cell / Q000000981:diagnostic imaging / Q000473:pathology / Q000532:radiotherapy*; D002945:Cisplatin / Q000627:therapeutic use; D003037:Cobalt Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008168:Lung / Q000000981:diagnostic imaging / Q000473:pathology; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology / Q000532:radiotherapy*; D008207:Lymphatic Metastasis / Q000532:radiotherapy; D008297:Male; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D017063:Outcome Assessment, Health Care; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use; D016634:Radiosurgery / Q000009:adverse effects / Q000379:methods*; D012189:Retrospective Studies; D014057:Tomography, X-Ray Computed
chemical_list: D003037:Cobalt Radioisotopes; D011838:Radiation-Sensitizing Agents; D002945:Cisplatin
keywords: Body cobalt based system; NSCLC; Radiation therapy; Stage III.